Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab dose escalation guided by trough serum concentrations in pediatric inflammatory bowel disease
2015-001653-32Phase 4
- Sponsor
- Janssen Scientific Affairs
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of infliximab in inflammatory bowel disease (IBD), Crohn's disease and autoimmune colitis, sponsored by Janssen Scientific Affairs. Primary endpoint: Change from baseline in clinical response at Week 16 after dose escalation.
02
Drugs
infliximab
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on 2015-001653-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001653-32.